Skip to main content
. 2016 Dec 20;26(2):333–343. doi: 10.1093/hmg/ddw389

Figure 2.

Figure 2.

Increased expression of secreted antagonists of WNT/β-catenin signalling in hearts of LmnaH222P/H222P mice and human subjects with LMNA cardiomyopathy. (A) Expression of sFRP1, sFRP2, Frbz and Dkk3 mRNA in hearts from 3 month-old and 6 month-old male LmnaH222P/H222P (H222P) and wild type (WT) mice. Error bars represent means ± standard errors of means (n = 7). *P < 0.05, ***P < 0.0005. (B) Representative immunoblots showing sFRP1 expression in hearts from 6 month-old male H222P and WT mice. (C) Representative immunoblot showing Dkk3 expression in explanted hearts from control human subjects and human subjects with cardiomyopathy and LMNA point mutations (LMNA patients). Erk1/2 is the loading control (45). Migrations of molecular mass standards in kilodaltons (kDa) are indicated at the right of the blots in panels B and C.